Alto Neuroscience director granted 10,958 stock options

Alto Neuroscience, Inc. director York Gwill received a grant of stock options covering 10,958 shares of common stock at an exercise price of $24.63 per share.

Rhea-AI Filing Summary

Alto Neuroscience, Inc. director York Gwill received a grant of stock options covering 10,958 shares of common stock at an exercise price of $24.63 per share. The options were issued under the company’s Non-Employee Director Compensation Policy and required no cash payment by Gwill.

The options will vest on the earlier of the one-year anniversary of the grant date and the company’s next annual meeting, as long as Gwill continues to serve through that vesting date. After this grant, he holds options for 10,958 underlying shares directly.

Insider Trade Summary

Grant/Award: 10,958 shares

Grant/Award 1 txn

Insider York Gwill

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	10,958	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 10,958 contracts (Direct)

Footnotes (2)

1. F1. The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.
2. F2. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

Key Figures

Options granted: 10,958 shares Exercise price: $24.63 per share Options after transaction: 10,958 shares +2 more

5 metrics

Options granted 10,958 shares Stock option grant to director York Gwill

Exercise price $24.63 per share Strike price of granted stock options

Options after transaction 10,958 shares Total option holdings reported following grant

Expiration date May 11, 2036 Option expiration for York Gwill’s grant

Grant consideration $0.00 per option No cash paid for derivative securities at grant

Key Terms

Stock Option (right to buy), Non-Employee Director Compensation Policy, continuous service, exercise price

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Non-Employee Director Compensation Policy financial

"issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy"

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

exercise price financial

"conversion_or_exercise_price: "24.6300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alto Neuroscience (ANRO) disclose about York Gwill in this Form 4?

Alto Neuroscience reported that director York Gwill received a grant of stock options for 10,958 shares of common stock as part of director compensation, giving him the right to buy shares at a fixed exercise price if the options vest.

How many Alto Neuroscience (ANRO) options did York Gwill receive?

York Gwill received stock options covering 10,958 shares of Alto Neuroscience common stock. These options give him the right to purchase that number of shares at a preset exercise price if vesting conditions based on his continued board service are satisfied.

What is the exercise price of York Gwill’s Alto Neuroscience (ANRO) stock options?

The stock options granted to York Gwill carry an exercise price of $24.63 per share. This means he can purchase Alto Neuroscience common shares at $24.63 if the options vest and he later chooses to exercise them during the option term.

When do York Gwill’s Alto Neuroscience (ANRO) options vest?

The options will vest on the earlier of the one-year anniversary of the grant date and Alto Neuroscience’s next annual meeting. Vesting is conditioned on York Gwill’s continuous service as a director through that vesting date, aligning compensation with ongoing board involvement.

Did York Gwill pay cash for the Alto Neuroscience (ANRO) options?

York Gwill did not pay any cash consideration for the stock options. The options were issued to him under Alto Neuroscience’s Non-Employee Director Compensation Policy, reflecting equity-based compensation rather than a market purchase of derivative securities.

How many Alto Neuroscience (ANRO) option shares does York Gwill hold after this grant?

Following this grant, York Gwill holds options covering 10,958 underlying shares of Alto Neuroscience common stock. This reflects his direct option position reported in the filing and represents his current derivative equity exposure from this specific award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

York Gwill

(Last) (First) (Middle)

C/O ALTO NEUROSCIENCE, INC.

650 CASTRO STREET, SUITE 450

(Street)

MOUNTAIN VIEW CALIFORNIA 94041

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$24.63	05/12/2026		A		10,958		(1)	05/11/2036	Common Stock	10,958	$0(2)	10,958	D

Explanation of Responses:

1. The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

2. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

Remarks:

	/s/ Erin R. McQuade, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)